Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

Journal of Experimental Medicine

Volumn 210, Issue 11, 2013, Pages 2435-2466

  Bos, Paula D ^a   Plitas, George ^a   Rudra, Dipayan ^a   Lee, Sue Y ^a   Rudensky, Alexander Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPHTHERIA TOXIN; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; IMMUNE RESPONSE; IONIZING RADIATION; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE DEPLETION; MAMMARY NEOPLASMS, ANIMAL; MICE; ONCOGENES; RADIATION, IONIZING; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84886805255     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20130762     Document Type: Article

References (51)

1. Ascierto, P.A., M. Kalos, D.A. Schaer, M.K. Callahan, and J.D. Wolchok. 2013. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin. Cancer Res. 19:1009-1020. http://dx.doi.org/10.1158/1078-0432.CCR-12-2982
2. Balachandran, V.P., M.J. Cavnar, S. Zeng, Z.M. Bamboat, L.M. Ocuin, H. Obaid, E.C. Sorenson, R. Popow, C. Ariyan, F. Rossi, et al. 2011. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17:1094-1100. http://dx.doi.org/10.1038/nm.2438
3. Barber, D.L., E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, A.H. Sharpe, G.J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 439:682-687. http://dx.doi.org/10.1038/nature04444
4. Brahmer, J.R., S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455-2465. http://dx.doi.org/10.1056/NEJMoa1200694
5. Chen, L., and D.B. Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13:227-242. http://dx.doi.org/10.1038/nri3405
6. Coussens, L.M., L. Zitvogel, and A.K. Palucka. 2013. Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science. 339:286-291. http://dx.doi.org/10.1126/science.1232227
7. Curran, M.A., W. Montalvo, H. Yagita, and J.P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA. 107:4275-4280. http://dx.doi.org/10.1073/pnas.0915174107
8. Demaria, S., N. Kawashima, A.M. Yang, M.L. Devitt, J.S. Babb, J.P. Allison, and S.C. Formenti. 2005. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11:728-734.
9. DeNardo, D.G., J.B. Barreto, P. Andreu, L. Vasquez, D. Tawfik, N. Kolhatkar, and L.M. Coussens. 2009. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 16:91-102. http://dx.doi.org/10.1016/j.ccr.2009.06.018
10. Drake, C.G. 2012. Combination immunotherapy approaches. Ann. Oncol. 23:viii41-6. http://dx.doi.org/10.1093/annonc/mds262
11. Facciabene, A., G.T. Motz, and G. Coukos. 2012. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72:2162-2171. http://dx.doi.org/10.1158/0008-5472.CAN-11-3687
12. Formenti, S.C., and S. Demaria. 2009. Systemic effects of local radiotherapy. Lancet Oncol. 10:718-726. http://dx.doi.org/10.1016/S1470-2045(09)70082-8
13. Fransen, M.F., T.C. van der Sluis, F. Ossendorp, R. Arens, and C.J. Melief. 2013. Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects. Clin. Cancer Res. In press.
14. Gasteiger, G., S. Hemmers, M.A. Firth, A. Le Floc'h, M. Huse, J.C. Sun, and A.Y. Rudensky. 2013. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J. Exp. Med. 210:1167-1178. http://dx.doi.org/10.1084/jem.20122462
15. Guy, C.T., R.D. Cardiff, and W.J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954-961. Heimann, R., and S. Hellman. 2000. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J. Clin. Oncol. 18:591-599.
16. Heimann, R., and S. Hellman. 2000. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J. Clin. Oncol. 18:591-599.
17. Hodi, F.S., S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723. http://dx.doi.org/10.1056/NEJMoa1003466
18. Hurwitz, A.A., B.A. Foster, E.D. Kwon, T. Truong, E.M. Choi, N.M. Greenberg, M.B. Burg, and J.P. Allison. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60:2444-2448.
19. Kaplan, D.H., V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, and R.D. Schreiber. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95:7556-7561. http://dx.doi.org/10.1073/pnas.95.13.7556
20. Kim, J.M., J.P. Rasmussen, and A.Y. Rudensky. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:191-197. http://dx.doi.org/10.1038/ni1428
21. Kim, J., K. Lahl, S. Hori, C. Loddenkemper, A. Chaudhry, P. deRoos, A. Rudensky, and T. Sparwasser. 2009. Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J. Immunol. 183:7631-7634. http://dx.doi.org/10.4049/jimmunol.0804308
22. Klages, K., C.T. Mayer, K. Lahl, C. Loddenkemper, M.W. Teng, S.F. Ngiow, M.J. Smyth, A. Hamann, J. Huehn, and T. Sparwasser. 2010. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 70:7788-7799. http://dx.doi.org/10.1158/0008-5472.CAN-10-1736
23. Komatsu, N., and S. Hori. 2007. Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc. Natl. Acad. Sci. USA. 104:8959-8964. http://dx.doi.org/10.1073/pnas.0702004104
24. Li, X., E. Kostareli, J. Suffner, N. Garbi, and G.J. Hämmerling. 2010. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol. 40:3325-3335. http://dx.doi.org/10.1002/eji.201041093
25. Lin, E.Y., J.G. Jones, P. Li, L. Zhu, K.D. Whitney, W.J. Muller, and J.W. Pollard. 2003. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163:2113-2126. http://dx.doi.org/10.1016/S0002-9440(10)63568-7
26. Lucas, J.A., J. Menke, W.A. Rabacal, F.J. Schoen, A.H. Sharpe, and V.R. Kelley. 2008. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181:2513-2521.
27. Minn, A.J., G.P. Gupta, D. Padua, P. Bos, D.X. Nguyen, D. Nuyten, B. Kreike, Y. Zhang, Y. Wang, H. Ishwaran, et al. 2007. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl. Acad. Sci. USA. 104:6740-6745. http://dx.doi.org/10.1073/pnas.0701138104
28. Mokyr, M.B., T. Kalinichenko, L. Gorelik, and J.A. Bluestone. 1998. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58:5301-5304.
29. O'Sullivan, T., R. Saddawi-Konefka, W. Vermi, C.M. Koebel, C. Arthur, J.M. White, R. Uppaluri, D.M. Andrews, S.F. Ngiow, M.W. Teng, et al. 2012. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 209:1869-1882. http://dx.doi.org/10.1084/jem.20112738
30. Pardoll, D.M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12:252-264. http://dx.doi.org/10.1038/nrc3239
31. Peggs, K.S., S.A. Quezada, C.A. Chambers, A.J. Korman, and J.P. Allison. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206:1717-1725. http://dx.doi.org/10.1084/jem.20082492
32. Podsypanina, K., K. Politi, L.J. Beverly, and H.E. Varmus. 2008. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc. Natl. Acad. Sci. USA. 105:5242-5247. http://dx.doi.org/10.1073/pnas.0801197105
33. Postow, M.A., J. Harding, and J.D. Wolchok. 2012. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J. 18:153-159. http://dx.doi.org/10.1097/PPO.0b013e318250c001
34. Quezada, S.A., K.S. Peggs, M.A. Curran, and J.P. Allison. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116:1935-1945. http://dx.doi.org/10.1172/JCI27745
35. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207:637-650. http://dx.doi.org/10.1084/jem.20091918
36. Sato, E., S.H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A.A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al. 2005. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA. 102:18538-18543. http://dx.doi.org/10.1073/pnas.0509182102
37. Schreiber, R.D., L.J. Old, and M.J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 331:1565-1570. http://dx.doi.org/10.1126/science.1203486
38. Selby, M.J., J.J. Engelhardt, M. Quigley, K.A. Henning, T. Chen, M. Srinivasan, and A.J. Korman. 2013. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunology Research. 1:32-42. http://dx.doi.org/10.1158/2326-6066.CIR-13-0013
39. Shankaran, V., H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, and R.D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107-1111. http://dx.doi.org/10.1038/35074122
40. Simpson, T.R., F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J.Y. Henry, H. Yagita, J.D. Wolchok, et al. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells codefines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210:1695-1710. http://dx.doi.org/10.1084/jem.20130579
41. Strome, S.E., H. Dong, H. Tamura, S.G. Voss, D.B. Flies, K. Tamada, D. Salomao, J. Cheville, F. Hirano, W. Lin, et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63:6501-6505.
42. Tan, W., W. Zhang, A. Strasner, S. Grivennikov, J.Q. Cheng, R.M. Hoffman, and M. Karin. 2011. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 470:548-553. http://dx.doi.org/10.1038/nature09707
43. Teng, M.W., S.F. Ngiow, B. von Scheidt, N. McLaughlin, T. Sparwasser, and M.J. Smyth. 2010. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 70:7800-7809. http://dx.doi.org/10.1158/0008-5472.CAN-10-1681
44. Topalian, S.L., C.G. Drake, and D.M. Pardoll. 2012a. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24:207-212. http://dx.doi.org/10.1016/j.coi.2011.12.009
45. Topalian, S.L., F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, et al. 2012b. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-2454. http://dx.doi.org/10.1056/NEJMoa1200690
46. van Elsas, A., A.A. Hurwitz, and J.P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190:355-366. http://dx.doi.org/10.1084/jem.190.3.355
47. van Elsas, A., R.P. Sutmuller, A.A. Hurwitz, J. Ziskin, J. Villasenor, J.P. Medema, W.W. Overwijk, N.P. Restifo, C.J. Melief, R. Offringa, and J.P. Allison. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:481-489. http://dx.doi.org/10.1084/jem.194.4.481
48. Waitz, R., S.B. Solomon, E.N. Petre, A.E. Trumble, M. Fassò, L. Norton, and J.P. Allison. 2012. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72:430-439. http://dx.doi.org/10.1158/0008-5472.CAN-11-1782
49. + CD25(Hi) regulatory T cells. Int. Immunol. 21:1065-1077. http://dx.doi.org/10.1093/intimm/dxp072
50. Willimsky, G., and T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 437:141-146. http://dx.doi.org/10.1038/nature03954
51. Wing, K., Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T. Nomura, and S. Sakaguchi. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 322:271-275. http://dx.doi.org/10.1126/science.1160062